Who Paid My Doc
Robert Gross
Pediatric Ophthalmology and Strabismus Specialist Dallas, TX Medical Doctor
NPI 1316944234 CMS profile 196056
7150 Greenville Ave Ste 305, Dallas, TX 75231
General payments
$7,635
Research payments
$0
Ownership & investment interest
$199,985
Through program year 2023, Robert Gross of Dallas, TX is reported in the CMS Open Payments database as having received $7,635 across 13 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $199,985 across 2 holdings.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 94th percentile of Pediatric Ophthalmology and Strabismus Specialist profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2023 | General | $15 | 1 | |
| 2021 | General | $2,368 | 5 | |
| 2020 | General | $15 | 1 | |
| 2019 | General | $5,237 | 6 | |
| 2022 | Ownership | $99,993 | 1 | |
| 2021 | Ownership | $99,993 | 1 |
Beside peers
- Robert Gross
- Pediatric Ophthalmology and Strabismus Specialist median
- Middle half of Pediatric Ophthalmology and Strabismus Specialist
- National median
In program year 2025, general payments to Robert Gross were reported at $0. Among 124 Pediatric Ophthalmology and Strabismus Specialist profiles paid that year, the median was $118 and the middle half received between $36 and $253.
Show as a table
| Year | Robert Gross | Pediatric Ophthalmology and Strabismus Specialist median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $5,237 | $106 | $24–$276 | $163 |
| 2020 | $15 | $54 | $19–$171 | $114 |
| 2021 | $2,368 | $118 | $25–$225 | $132 |
| 2022 | $0 | $97 | $40–$324 | $149 |
| 2023 | $15 | $139 | $78–$441 | $160 |
| 2024 | $0 | $114 | $35–$313 | $164 |
| 2025 | $0 | $118 | $36–$253 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
13 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Pediatric Ophthalmology and Strabismus Specialist in Texas
Charlotte Akor
Pediatric Ophthalmology and Strabismus Specialist · Corpus Christi, TX
Erica Luse
Pediatric Ophthalmology and Strabismus Specialist · Houston, TX
Adam Cantor
Pediatric Ophthalmology and Strabismus Specialist · Houston, TX
Jessica Thayer
Pediatric Ophthalmology and Strabismus Specialist · Frisco, TX
David Weakley
Pediatric Ophthalmology and Strabismus Specialist · Dallas, TX
Serena Wang
Pediatric Ophthalmology and Strabismus Specialist · Dallas, TX
Related records
Pediatric Ophthalmology and Strabismus Specialist in Texas
Practitioners in the same specialty and state, ranked by reported value.
All Pediatric Ophthalmology and Strabismus Specialist
Everyone recorded under this specialty, nationwide.
Doctors in Texas
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.